Biomedicine & Pharmacotherapy · 2019 · 116 citations · 51 references
PharmacyOncologyPharmacologyChemotherapyDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineDrug EncapsulationNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignPeptide ProdrugsCancer NanotherapyNanocarrier-based ProdrugsNanoparticle-based ChemotherapyNanoparticlesOvercoming Multidrug ResistancePeptide-linked ProdrugsTumor-targeted Peptide ProdrugsTumor-targeted Ph-activated Prodrugs
Lung cancer is the leading cause of cancer death worldwide. To overcome the toxic side effects and multidrug resistance (MDR) during doxorubicin (DOX) chemotherapy, a urokinase plasminogen activator receptor (uPAR) targeting U11 peptide decorated, pH-sensitive, dual drugs co-encapsulated nanoparticles (NPs) system is employed in this study. A U11 peptide conjugated, pH-sensitive DOX prodrug (U11-DOX) was synthesized and used as materials to produce NPs. A curcumin (CUR) and U11-DOX co-encapsulated NPs system (U11-DOX/CUR NPs) was constructed to treat lung cancer. After the characterization of biophysical properties of this NPs system, synergistic chemotherapeutic efficacy was evaluated in both cultured cancer cells and tumor-bearing animal model. U11-DOX/CUR NPs had a uniformly spherical shape with a core-shell structure. The mean particle size and zeta potential of the U11-DOX/CUR NPs was 121.3 nm and -33.5 mV, with a DOX and CUR EE of 81.7 and 90.5%, respectively. The DOX release from U11-DOX/CUR NPs was 83.5, 55.2, and 32.8% correspondence to the pH of 5.0, 6.0 and 7.4. Cellular uptake efficiency of U11-DOX/CUR NPs was significantly higher than non U11 peptide decorated DOX/CUR NPs. U11-DOX/CUR NPs displayed a pronounced synergy effects in vitro and an obvious tumor tissue accumulation efficiency in vivo. In vivo antitumor experiment showed that U11-DOX/CUR NPs could inhibit the tumor growth to a level of 85%.In vitro and in vivo studies demonstrated that U11-DOX/CUR NPs is a sustained released, pH responsive, synergistic antitumor system. This study suggests that the U11-DOX/CUR NPs have promising potential for combination treatment of lung cancer.
51
Role of nanoparticle size, shape and surface chemistry in oral drug delivery
Amrita Banerjee, Jianping Qi, Rohan Gogoi et al. · Journal of Controlled Release · 2016 · 750 citations
Vendula Pospíchalová, Jan Svoboda, Zankruti Dave et al. · Journal of Extracellular Vesicles · 2015 · 394 citations · Full text
Kevin S. Chu, Warefta Hasan, Sumit Rawal et al. · Nanomedicine Nanotechnology Biology and Medicine · 2012 · 152 citations · Full text